Grifols
Global healthcare company focused on research, development, manufacture and commercialization of plasma-derived medicines, diagnostic assays and biological materials. Operates an international plasma donation center network and multiple manufacturing sites with vertically integrated processes from donor collection to patient delivery. Maintains integrated R&D programs and is diversifying into recombinant protein candidates and small-molecule therapeutics.
Industries
Nr. of Employees
Very Large (1000+)
Patents
System and method for efficiently transferring receptacles out of a receptacle storage area
US-12709479-B2
View DetailsAutomated processing of samples carried in sample containers and grouping sample containers according to assays to be performed on samples contained therein
US-12699109-B2
View DetailsContainer for a solution of human plasma proteins and method for obtaining thereof
US-11458070-B2
View Details
System and method for efficiently transferring receptacles out of a receptacle storage area
US-12709479-B2
View DetailsAutomated processing of samples carried in sample containers and grouping sample containers according to assays to be performed on samples contained therein
US-12699109-B2
View DetailsContainer for a solution of human plasma proteins and method for obtaining thereof
US-11458070-B2
View DetailsServices
Research, development, GMP manufacture and commercialization of therapies derived from human plasma, and development of recombinant and small-molecule therapeutic candidates.
Development and provision of diagnostic assays, laboratory instruments and automation to support disease detection and laboratory workflows.
Supply, qualification and distribution of plasma and other biological materials for research, clinical trials and manufacturing of diagnostics and therapeutics.
Products, technical support and operational services aimed at hospital pharmacies and clinical units to support safe therapy delivery and patient care.
Engineering consultancy, design and construction services for biopharmaceutical manufacturing facilities, including sterile filling lines, controlled environments and automation integration.
Research, development, GMP manufacture and commercialization of therapies derived from human plasma, and development of recombinant and small-molecule therapeutic candidates.
Development and provision of diagnostic assays, laboratory instruments and automation to support disease detection and laboratory workflows.
Supply, qualification and distribution of plasma and other biological materials for research, clinical trials and manufacturing of diagnostics and therapeutics.
Products, technical support and operational services aimed at hospital pharmacies and clinical units to support safe therapy delivery and patient care.
Engineering consultancy, design and construction services for biopharmaceutical manufacturing facilities, including sterile filling lines, controlled environments and automation integration.
Expertise Areas
- Plasma-derived therapeutics development and manufacturing
- Recombinant protein and small-molecule therapeutic development
- Transfusion medicine and blood safety
- Diagnostic assay development and laboratory automation
Key Technologies
- Plasma fractionation
- Protein purification and downstream processing
- Serology platforms (ELISA, agglutination, gel-column)
- Nucleic acid testing (NAT)
News & Updates
Integrated annual report covering financial and non-financial performance aligned with CSRD, GRI and SASB.
Renewable energy purchase agreement to cover more than half of electricity consumption in Spain.
Announcement of last patient visit in a Phase 3 outcomes study for an alpha-1 antitrypsin deficiency treatment.
Financial results reporting revenue increases and net profit changes for the reporting period to June.
Listed by Time as one of the world's most impactful companies in multiple years.
Included in Forbes' World's Best Employers lists (mentioned for 2024 and 2025).
Integrated annual report covering financial and non-financial performance aligned with CSRD, GRI and SASB.
Renewable energy purchase agreement to cover more than half of electricity consumption in Spain.
Announcement of last patient visit in a Phase 3 outcomes study for an alpha-1 antitrypsin deficiency treatment.
Financial results reporting revenue increases and net profit changes for the reporting period to June.
Listed by Time as one of the world's most impactful companies in multiple years.
Included in Forbes' World's Best Employers lists (mentioned for 2024 and 2025).